July 30, 2018 / 8:39 PM / in 15 days

BRIEF-Novartis says European Commission Approved Aimovig For Prevention Of Migraine In Adults Experiencing Four Or More Migraine Days Per Month

July 30 (Reuters) - Novartis AG:

* NOVARTIS SAYS EUROPEAN COMMISSION APPROVED AIMOVIG (ERENUMAB) FOR PREVENTION OF MIGRAINE IN ADULTS EXPERIENCING FOUR OR MORE MIGRAINE DAYS PER MONTH

* EMA DECISION IS APPLICABLE TO ALL 28 EUROPEAN UNION MEMBER STATES PLUS ICELAND, NORWAY AND LIECHTENSTEIN

* NOVARTIS POST-APPROVAL ACCESS PROGRAM OPENED TO GIVE AIMOVIG IN NATIONS WHERE LOCAL REGULATIONS ALLOW PROVISION OF UNAPPROVED OR YET TO BE REIMBURSED THERAPIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below